BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 24, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Northera droxidopa: Extension study data

Top-line data from the 3-month, open-label phase of the Study 303 extension study in 75 patients showed that Northera significantly decreased OHQ composite scores by a mean of 3.2 units from baseline (p<0.001). Additionally, minimal or no orthostatic hypotension was observed in 58% of Parkinson's disease patients and 47% of all patients at 3 months compared with 3% and 1%, respectively, at baseline. Furthermore, Northera significantly...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >